Combined 18F‑DOPA PET and multimodal MRI versus multimodal MRI alone on detecting high-grade subregions of glioma

Takeaway

  • Addition of [18F]-dihydroxyphenylalanine positron-emission tomography (18F‑DOPA PET) to multimodal magnetic resonance imaging (MRI) improved the detection of high-grade subregions in treatment-naive patients with enhancing or non-enhancing glioma.

Why this matters

  • Gliomas are a group of highly heterogeneous tumors, with possible coexisting high- and low-grade subregions where the neoplastic cells can infiltrate far beyond the tumor core, and cannot be cured with surgery.

  • Identification of the high-grade subregions prior to surgery is crucial, as it may affect the accuracy of pathological diagnosis.

  • MRI, perfusion-weighted imaging (PWI) and amino-acid PET (including 18F-DOPA PET) are used for detecting non-enhancing high-grade glioma (HGG) subregions. However, MRI with contrast enhancement (CE) does not always reveal all the extents of HGG subregions of glioma.

  • Adding 18F-DOPA PET to multimodal MRI (CE and PWI) is of interest to improve treatment planning for patients newly diagnosed with glioma.